1nhaler, a Scotland-based drug delivery device developer, has secured 2.2 million GBP in follow-on funding to progress its novel pop-up cardboard inhaler towards first regulatory approval.
The investment will facilitate late-stage development of 1nhaler’s lead product, 1nhaler Salbutamol, which combines the novel device with salbutamol, a well-established asthma medicine. The company says the funding will complete the technical transfer of this product into contract manufacturing for the production of clinical trial material and progress a small clinical trial to support regulatory filing, targeted for late 2027.
Lisa McMyn, co-founder and Chief Executive Officer at 1nhaler said: Lisa McMyn, co-founder and Chief Executive Officer at 1nhaler, said: “This investment takes us to one of the most important milestones in our journey – taking our own lead product into the clinic. The continued backing of Archangels, Scottish Enterprise and BBB Investments reflects the technical and commercial progress we have made over the past year.”
The funding will also support a manufacturing engineering study with industry leaders, Harro Höfliger for the commercial scale-up of the 1nhaler dry powder inhaler (DPI) and enable the 1nhaler team to advance business development discussions with parties interested in the utility and innovation of the 1nhaler platform and its lead product.
Inhalable medicines are already used to treat conditions such as asthma, COPD, influenza, epilepsy, depression and Parkinson’s. 1nhaler’s unique single-dose DPI platform is designed to address key limitations in current delivery options around user accessibility, cost and environmental impact.
1nhaler says its single-dose DPI is made predominantly from cardboard and is the size and shape of a credit card, unlike traditional inhalers made from plastic. It transforms into a three-dimensional inhaler for patient use and, with few components including the patent-protected membrane-based system, is designed to be simpler and more affordable to manufacture at scale.
The company claims that beyond respiratory conditions, the platform has the potential to deliver dry powder medicines for a range of other uses, including pain relief and vaccines.
Dr Sarah Hardy, Director and Head of New Investments at Archangels said: “Having backed 1nhaler since 2023, we see this latest round as a reflection of our confidence in the team and its novel inhaler device that has the potential to disrupt the global market for inhaled medicines. We are particularly excited by the commercial traction and interest from potential partners across a broader range of drugs than we initially anticipated, highlighting the platform’s versatility and market potential. Taking this product into a clinical study is a significant milestone towards demonstrating its performance in patients. Working alongside our co-investors, we look forward to supporting 1nhaler through its next stage of growth as it builds towards regulatory approval and commercialisation.”
Derek Shaw, Director of Company Funding and Investment at Scottish Enterprise said: ‘This investment highlights our dedication to supporting the growth of ambitious businesses in Scotland. By helping these companies scale, we aim to empower them to compete and lead in global markets. Scotland has distinct global strengths in industries such as human health and fostering the development of companies such as 1nhaler is key to sustaining their success and driving future growth.’
The funding round was led by Archangels with support from Scottish Enterprise and BBB Investments.
